New hope for stubborn GIST: experimental drug DCC-2618 enters safety testing
NCT ID NCT07618377
First seen Jun 05, 2026 · Last updated Jun 13, 2026 · Updated 1 time
Summary
This early-stage study tests the safety of an experimental drug called DCC-2618 in 10 people with advanced gastrointestinal stromal tumor (GIST) that has not responded to or cannot tolerate at least three prior treatments. The main goal is to see what side effects occur. This is not a cure, but aims to control the disease in patients with few remaining options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center Hospital
Tokyo, Chuo-ku, Japan
-
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.